Abstract 4287
Background
For patients with mCRC that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. In these secondary analyses of the OZONE study, aflibercept + FOLFIRI safety and efficacy was evaluated for sub-populations of patients with mCRC.
Methods
OZONE is a prospective, multicentre, observational, non-comparative study evaluating patients receiving aflibercept + FOLFIRI in the clinical setting, for 24 months from aflibercept initiation or until death. Patients were grouped according to: age (≥ 65 years vs < 65 years); renal (CrCl ≤ 80 mL/min) or hepatic (bilirubin > UNL or AST/ALT > 1.5 UNL) impairment; number and type of prior anti-cancer therapy.
Results
From the overall population (N = 766), there were 370 patients aged ≥ 65 years. All grade asthenia (43.5% vs 35.9%) and decreased appetite (25.4% vs 20.2%) occurred more frequently (≥ 5%) in patients aged ≥ 65 vs < 65 years. There were 256 patients with CrCl ≤ 80 mL/min, of which 43 had CrCl < 50 mL/min. Renal function did not influence treatment-emergent adverse events (TEAEs). Grade ≥ 3 TEAEs were reported in 76.7%, 67.1% and 67.9% of patients with CrCl < 50 mL/min, CrCl 50–80 mL/min, and CrCl > 80 mL/min, respectively. There were 129 patients with impaired liver function. All grade constipation and haemorrhage were more frequent in patients with impaired liver function vs those without (23.3% vs 14.2% and 37.2% vs 30.1%, respectively). There were 449 patients previously treated with bevacizumab. Only fatigue occurred more frequently in patients with prior bevacizumab vs those without (23.8% vs 17.0%). Efficacy multivariate analyses showed that treatment with aflibercept + FOLFIRI favoured patients without vs with hepatic impairment (median overall survival [OS] 13.7 vs 8.7 months; p < 0.001) and without vs with prior use of bevacizumab (median OS 16.6 vs 10.6 months; p < 0.001).
Conclusions
Subgroup analyses of the OZONE study did not reveal major differences in the safety profile according to age, renal or hepatic status, or prior bevacizumab status. These results suggest that aflibercept may be a treatment option for these subgroups of patients. Funding: Sanofi.
Clinical trial identification
ENCEPP/SDPP/4836.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
I. Chau: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eli-Lilly; Advisory / Consultancy: Bristol Meyers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (self): Merck-Serono; Advisory / Consultancy: Five Prime Therapeutics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Oncologie International; Advisory / Consultancy: Pierre Fabre; Research grant / Funding (self): Janssen-Cilag; Research grant / Funding (self): Sanofi Oncology. P. García-Alfonso: Advisory / Consultancy: Amgen; Advisory / Consultancy: Bristol Meyers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck-Serono; Advisory / Consultancy: Sanofi Oncology; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Servier. Z. Linke: Advisory / Consultancy, Advisory Board- Oncologic days in Bratislava, Slovakia, 2016, 2017, 2018 and Prague in 2018.: Sanofi; Speaker Bureau / Expert testimony, Lecture- Prague Onco 2019: Merck; Non-remunerated activity/ies, ESMO 2017: Roche. A. Ruiz-Casado: Research grant / Funding (self): Sanofi; Research grant / Funding (self): Servier; Research grant / Funding (self): Amgen; Research grant / Funding (self): Merck; Research grant / Funding (self): Lilly; Research grant / Funding (self): Roche; Research grant / Funding (self): Medtronic; Research grant / Funding (self): BTG. E. Polo Marques: Research grant / Funding (self): Roche; Research grant / Funding (self): Amgen; Research grant / Funding (self): Sanofi; Research grant / Funding (self): Merck. T. Cartwright: Research grant / Funding (self): Amgen; Research grant / Funding (self): Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract